Navigation Links
Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
Date:2/24/2010

As a result of this request, Shire withdrew its December BLA filing, and, at the suggestion of the FDA, requested and received Fast Track designation. Shire will immediately initiate the rolling submission of the REPLAGAL BLA, and will submit the requested pharmacokinetic data around mid-year.

Fast Track designation is an FDA-approved process that facilitates the development and expedites the review of drugs to treat serious diseases and fill an unmet medical need with the goal of getting important new treatments to patients earlier. This process allows a company to file the sections of the BLA as they become available instead of filing all the sections at once. It also enables the agency to commence its review and proceed on a rolling basis as the additional sections are completed and submitted for review.

"We will continue to work closely with the FDA in the coming months on the rolling BLA submission for REPLAGAL, "said Sylvie Gregoire, President, Shire Human Genetic Therapies. "We remain committed to continuing to provide Fabry patients in the United States with REPLAGAL under the treatment protocol."

REPLAGAL
'/>"/>

SOURCE Shire Pharmaceutical
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
2. New Shire Board Member
3. Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease
4. New CapSure™ Cleanroom Wiper from Berkshire Corporation Captures and Retains 42 Times More Contaminant Particles
5. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
6. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
7. Shire Initiates Two Adult ADHD Outreach Programs
8. Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
9. Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology
10. The Crohns & Colitis Foundation of America and Shire Launch Virtual IBD March on the Hill to Increase Funding for Digestive Disease Research
11. Shire begins the year with a strong performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... and difficult to manufacture proteins including biosimilar therapeutics, ... results for the second quarter ended June 30, ... our initial public offering, we have the capital ... derived from our proprietary protein expression platform," stated ...
(Date:8/29/2014)... based on electrons, but one of the most promising ... circuits based on light (photons) instead of electrons. First, ... stream of single photons and control their direction. Researchers ... to achieve this control, but now scientists at the ... stream of photons emitted one at a time and ...
(Date:8/29/2014)... 29, 2014 The global companion ... in 2019. It is expected to grow at ... and was valued at $1.8 billion in 2013, ... Market Research. , For more information regarding analysis ... , The research report, titled “Companion Diagnostics Market ...
(Date:8/29/2014)... 2014 According to a new market report ... orthobiologics market was valued at USD 3,754.6 million in 2012 ... in 2019at a CAGR of 5.9% from 2013 to 2019. ... above is afflicted by bone and joint disorders, and this ... This has and will continue to increase the demand for ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... XIANYANG, China, May 17 /PRNewswire-Asia-FirstCall/ -- Biostar,Pharmaceuticals, Inc. ... manufacturer of a leading over-the-counter Hepatitis B medicine, Xin,Aoxing Oleanolic ... announced financial results of the first quarter ended March,31, ... revenue increased 66.0% to $12.4 million, -- ...
... 17 Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the ... first quarter of 2010. , ... Soligenix,s revenues for the first quarter of 2010 were approximately ... of 2009. The decreased revenues were primarily a result of decreases in ...
... and MELVILLE, N.Y. May 16 ... Pharmaceuticals, Inc. (Nasdaq: OSIP ), a biotechnology company primarily focused ... medical needs in oncology, diabetes and obesity, today announced that they ... acquire OSI. , , ...
Cached Biology Technology:Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 2Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 3Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 4Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 5Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 6Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 7Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 8Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 9Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 10Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 11Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 12Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 13Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments 2Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments 3Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments 4Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments 5Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. 2Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. 3Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. 4Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. 5Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. 6
(Date:8/29/2014)... made some surprising discoveries about the body,s initial ... (SIV), the team found that specialized cells in ... to viral invasion and are the source of ... beta (IL-1β). , Though aimed at the ... gut epithelium that provides a barrier to protect ...
(Date:8/29/2014)... Scientists at the Barshop Institute for Longevity and Aging ... UT Health Science Center at San Antonio, have found ... longest-lived rodent, the naked mole rat. , They ... mole rats protects and alters the activity of the ... , The factor also protects proteasome function in human, ...
(Date:8/29/2014)... little has been known about what genetic changes transform ... scientists, one of whom is a University of Montana ... genes controlling the development of the brain and the ... study was published Aug. 28 in Science ... online at http://www.sciencemag.org/ ., The domestication of animals ...
Breaking Biology News(10 mins):The early cost of HIV 2Factor in naked mole rat's cells enhances protein integrity 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
... from the food industry are excellent sources of proteins ... However, at the moment these side streams are mainly ... end up as waste. Coordinated by VTT, the ... containing industrial co-streams) project seeks to enrich several co-stream ...
... is no scientific evidence that low-level electromagnetic field ... causes adverse health effects, according to a report ... the Committee provides advice to authorities about risk ... has assessed the health hazards from low-level electromagnetic ...
... Mass. and COLUMBIA, S.C., Sept. 17, 2012   Eliza Corporation ... engagement management, and BlueCross BlueShield of South Carolina ... rates for BlueCross members increased 45 percent over 2011 ... 2012 program have exceeded expectations in all areas, and ...
Cached Biology News:Food industry's high-quality co-streams used effectively as raw material for new products 2Mobile phones and wireless networks: No evidence of health risk found 2Mobile phones and wireless networks: No evidence of health risk found 3Mobile phones and wireless networks: No evidence of health risk found 4Eliza Corporation and BlueCross BlueShield of South Carolina Drive Awareness and Healthier Behavior to Increase Colorectal Cancer Screenings by 45 Percent 2Eliza Corporation and BlueCross BlueShield of South Carolina Drive Awareness and Healthier Behavior to Increase Colorectal Cancer Screenings by 45 Percent 3Eliza Corporation and BlueCross BlueShield of South Carolina Drive Awareness and Healthier Behavior to Increase Colorectal Cancer Screenings by 45 Percent 4
Guanylate Kinase Purified Anti-Mouse, Anti-Rat clone 28, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
...
Proliferin (C-14)...
... The Turn & Cast submarine gel systems used gasketed ... the gel in the tank. Turn it back and ... For added convenience, each Turn & Cast tray is ... near the edge of the tray and one in ...
Biology Products: